Snyder P J, Peachey H, Hannoush P, Berlin J A, Loh L, Holmes J H, Dlewati A, Staley J, Santanna J, Kapoor S C, Attie M F, Haddad J G, Strom B L
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
J Clin Endocrinol Metab. 1999 Jun;84(6):1966-72. doi: 10.1210/jcem.84.6.5741.
As men age, their serum testosterone concentrations decrease, as do their bone densities. Because bone density is also low in hypogonadal men, we hypothesized that increasing the serum testosterone concentrations of men over 65 yr to those found in young men would increase their bone densities. We randomized 108 men over 65 yr of age to wear either a testosterone patch or a placebo patch double blindly for 36 months. We measured bone mineral density by dual energy x-ray absorptiometry before and during treatment. Ninety-six men completed the entire 36-month protocol. The mean serum testosterone concentration in the men treated with testosterone increased from 367 +/- 79 ng/dL (+/-SD; 12.7 +/- 2.7 nmol/L) before treatment to 625 +/- 249 ng/dL (21.7 +/- 8.6 nmol/L; P < 0.001) at 6 months of treatment and remained at that level for the duration of the study. The mean bone mineral density of the lumbar spine increased (P < 0.001) in both the placebo-treated (2.5 +/- 0.6%) and testosterone-treated (4.2 +/- 0.8%) groups, but the mean changes did not differ between the groups. Linear regression analysis, however, demonstrated that the lower the pretreatment serum testosterone concentration, the greater the effect of testosterone treatment on lumbar spine bone density from 0-36 months (P = 0.02). This analysis showed a minimal effect (0.9 +/- 1.0%) of testosterone treatment on bone mineral density for a pretreatment serum testosterone concentration of 400 ng/dL (13.9 nmol/L), but an increase of 5.9 +/- 2.2% for a pretreatment testosterone concentration of 200 ng/dL (6.9 nmol/L). Increasing the serum testosterone concentrations of normal men over 65 yr of age to the midnormal range for young men did not increase lumbar spine bone density overall, but did increase it in those men with low pretreatment serum testosterone concentrations.
随着男性年龄增长,其血清睾酮浓度会下降,骨密度也会降低。由于性腺功能减退男性的骨密度也较低,我们推测将65岁以上男性的血清睾酮浓度提高到年轻男性的水平会增加他们的骨密度。我们将108名65岁以上的男性随机分为两组,双盲佩戴睾酮贴片或安慰剂贴片,为期36个月。在治疗前和治疗期间,我们通过双能X线吸收法测量骨矿物质密度。96名男性完成了整个36个月的方案。接受睾酮治疗的男性血清睾酮平均浓度从治疗前的367±79 ng/dL(±标准差;12.7±2.7 nmol/L)增加到治疗6个月时的625±249 ng/dL(21.7±8.6 nmol/L;P<0.001),并在研究期间保持在该水平。安慰剂治疗组(2.5±0.6%)和睾酮治疗组(4.2±0.8%)的腰椎平均骨矿物质密度均增加(P<0.001),但两组的平均变化无差异。然而,线性回归分析表明,治疗前血清睾酮浓度越低,睾酮治疗对0至36个月腰椎骨密度的影响越大(P = 0.02)。该分析显示,治疗前血清睾酮浓度为400 ng/dL(13.9 nmol/L)时,睾酮治疗对骨矿物质密度的影响最小(0.9±1.0%),而治疗前睾酮浓度为200 ng/dL(6.9 nmol/L)时,增加了5.9±2.2%。将65岁以上正常男性的血清睾酮浓度提高到年轻男性的正常范围中间值,总体上并未增加腰椎骨密度,但确实增加了治疗前血清睾酮浓度较低的男性的腰椎骨密度。